JUXTAPID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Juxtapid, and what generic alternatives are available?
Juxtapid is a drug marketed by Chiesi and is included in one NDA. There are eight patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries.
The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lomitapide mesylate profile page.
DrugPatentWatch® Generic Entry Outlook for Juxtapid
Juxtapid was eligible for patent challenges on December 21, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 7, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JUXTAPID?
- What are the global sales for JUXTAPID?
- What is Average Wholesale Price for JUXTAPID?
Summary for JUXTAPID
International Patents: | 27 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Clinical Trials: | 5 |
Drug Prices: | Drug price information for JUXTAPID |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JUXTAPID |
What excipients (inactive ingredients) are in JUXTAPID? | JUXTAPID excipients list |
DailyMed Link: | JUXTAPID at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JUXTAPID
Generic Entry Date for JUXTAPID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for JUXTAPID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aegerion Pharmaceuticals, Inc. | |
Amryt Pharma | |
Aegerion Pharmaceuticals, Inc. | Phase 1 |
Pharmacology for JUXTAPID
US Patents and Regulatory Information for JUXTAPID
JUXTAPID is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of JUXTAPID is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting JUXTAPID
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OFHYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-006 | Apr 23, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-004 | Apr 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-006 | Apr 23, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-004 | Apr 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-005 | Apr 23, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-004 | Apr 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JUXTAPID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-003 | Dec 21, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-004 | Apr 23, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-006 | Apr 23, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-001 | Dec 21, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-005 | Apr 23, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | JUXTAPID | lomitapide mesylate | CAPSULE;ORAL | 203858-002 | Dec 21, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for JUXTAPID
See the table below for patents covering JUXTAPID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Czech Republic | 9702617 | ⤷ Sign Up | |
Hungary | 9801278 | ⤷ Sign Up | |
Canada | 2213466 | INHIBITEURS DE LA PROTEINE MICROSOMALE DE TRANSFERT DES TRIGLYCERIDES ET METHODE D'UTILISATION (INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD) | ⤷ Sign Up |
Croatia | P20130115 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2005087234 | ⤷ Sign Up | |
Finland | 973416 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JUXTAPID
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1725234 | 2/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: LOMITAPID BZW. DESSEN PHARMAZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/13/851/001-EU/1/13/851/003 20130731 |
1725234 | C20140001 00107 | Estonia | ⤷ Sign Up | PRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013 |
1725234 | CR 2014 00002 | Denmark | ⤷ Sign Up | PRODUCT NAME: LOMITAPID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER PIPERIDIN N-OXIDET DERAF, HERUNDER LOMITAPIDMESYLAT; REG. NO/DATE: EU/1/13/851/001-003 20130805 |
1725234 | 122014000003 | Germany | ⤷ Sign Up | PRODUCT NAME: LOMITAPID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER DAS PIPERIDIN-N-OXID DAVON; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731 |
1725234 | 300634 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LOMITAPIDE OF HET PIPERIDINE N-OXIDE DAARVAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130805 |
1725234 | PA2014001,C1725234 | Lithuania | ⤷ Sign Up | PRODUCT NAME: LOMITAPIDAS; REGISTRATION NO/DATE: EU/1/13/851/001, 2013-07-31 EU/1/13/851/002, 2013-07-31 EU/1/13/851/003 20130731 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |